Clinical Trials
9 trialsNCT03997448 2024-02-20
Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149
Big Ten Cancer Research Consortium
Phase 2 Terminated
NCT03722108 2023-10-16
REGIRI
UNICANCER
Phase 1/2 Terminated
NCT03000179 2022-04-14
Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT01206296 2021-03-09
Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma
Medstar Health Research Institute
Phase 2 Terminated
NCT02487277 2020-01-02
PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma
University of California, San Francisco
Phase 2 Terminated
NCT00507702 2019-04-18
Identification of Key Blood Molecular Markers for Immunotherapy
Stanford University
Terminated
NCT00201734 2016-09-23
Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary
Ohio State University Comprehensive Cancer Center
Phase 1/2 Terminated
NCT00892242 2014-09-22
Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer
Washington University School of Medicine
Phase 1 Terminated
NCT01096732 2014-01-08
HIPPoS
Cambridge University Hospitals NHS Foundation Trust
Phase 2 Terminated